Binaytara Hematology and Breast Cancer Conference, Fresno

Fresno, CA US
April 20, 2024

We invite cancer care professionals to join the Binaytara Hematology and Breast Cancer Conference, Fresno, a CME-accredited event dedicated to hematology and breast cancer. This in-person conference gathers well known experts in hematology and breast cancer to explore the latest updates and research in these fields. Attendees will gain insights into how recent advancements are reshaping the standard of care for patients with hematologic malignancies and breast cancer. The conference emphasizes a multidisciplinary approach, focusing on integrating cutting-edge developments into patient-centric care.

Healthcare professionals attending this event will have opportunity to engage with leaders and peers in discussions about current research and progress in treating hematologic disorders and breast cancer. The Binaytara conference aims to critically evaluate significant clinical data and expert insights, aiming to enhance patient care and clinical outcomes.

Target Audience

  • Hematologists, Oncologists
  • Surgeons
  • Radiation Oncologists
  • Physician Assistants/Nurse Practitioners
  • Pharmacists
  • Nurses

ORGANIZING COMMITTEE 

Course Director:

Binay Shah, MD, MHA - Binaytara Foundation

Co-Chairs:

Haifaa Abdulhaq, MD - UCSF Fresno

Sanjay Hinduja, MD - UCSF Fresno

VENUE INFORMATION 

DoubleTree by Hilton Hotel Fresno Convention Center

Learning Objectives

  1. Review data presented at the ASH2023 and SABCS2023 & discuss their applications in clinical settings.    
  2. Choose new therapeutic options for treating benign and malignant hematologic disorders & breast cancer, understanding appropriate indications and contraindications to these therapeutic approaches.
  3. Discuss the study design and primary endpoints of recently reported and ongoing trials that have influenced the changes in the standards of care in hematology and breast cancer.
  4. Integrate evolving diagnostic, prognostic, and therapeutic approaches to managing hematologic disorders and breast cancer patients.
  5. Individualize management of patients based on emerging data from clinical trials and evolving expert guidelines.

GLOBAL ONCOLOGY PROJECT

To learn more about our ongoing project building a 200-bed cancer hospital in Nepal:

Course summary
Available credit: 
  • 6.50 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.50 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 6.50 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 6.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 6.50 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 6.50 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 6.50 Contact Hours.
Course opens: 
01/10/2024
Course expires: 
06/21/2024
Event starts: 
04/20/2024 - 8:00am PDT
Event ends: 
04/20/2024 - 4:30pm PDT
Cost:
$150.00

April 20th, 2024

All times are listed in Pacific Time (PT)

07:00 AM – 08:00 AM: Registration, Breakfast, & Exhibits


08:00 AM – 08:05 AM  Welcome 

08:05 AM – 8:20 AM  Binaytara Foundation's Efforts in Improving Cancer Care Disparities - Binay Shah, MD, MHA


08:20 AM – 09:50 AM  Session 1

Moderator: Xuan Ge, MD, PhD

08:20 AM – 08:45 AM  Lymphoma - Joseph Tuscano, MD

08:45 AM – 09:10 AM  Chronic Lymphocytic Leukemia - Haifaa Abdulhaq, MD

09:10 AM – 09:35 AM  Multiple Myeloma - Alfred Chung, MD

09:35 AM – 09:50 AM  Q & A


09:50 AM – 10:20 AM   Break & Exhibits


10:20 AM – 12:15 PM Session 2

Moderator: Matthew Frank, MD, PhD

10:20 AM – 10:30 AM   AML Case - Cathy Zhang, MD

10:30 AM – 10:50 AM  MDS/Acute Leukemia - Aaron Logan, MD, PhD

10:50 AM – 11:10 AM  Myeloproliferative Neoplasms and CML - Mohammed Bukari, MD, FACP

11:10 AM – 11:30 AM  Cellular Therapy in Hematologic Malignancies – Recent Updates - Vanessa Kennedy, MD

11:30 AM – 11:45 AM  Case 1 - Long Term Toxicities/Management of Cellular Therapy - Matthew Frank, MD, PhD

11:45 AM – 12:00 PM  Case 2 - Access to Cellular Therapy - Challenges - Naseem Esteghamat, MD, MS

12:00 PM – 12:15 PM  Q & A


12:15 PM – 01:15 PM  Lunch & Exhibits


01:15 PM – 02:45 PM  Session 3

Moderator: L. Lisa Ge, MD

01:15 PM – 01:40 PM  Triple Negative Breast Cancer - Christos Vaklavas, MD

01:40 PM – 02:05 PM  Hormone Receptor Positive Breast Cancer - Karen S. Anderson, MD, PhD

02:05 PM – 02:30 PM  HER2 Positive Breast Cancer - Mark Pegram, MD

02:30 PM – 02:45 PM  Q & A


02:45 PM – 03:00 PM  Break & Exhibits


03:00 PM – 04:35 PM  Session 4

Moderator: Andy S. Jang, MD

03:00 PM – 03:25 PM  Radiotherapy – Best Breast Practice - Long N. Pham, MD

03:25 PM – 03:35 PM  Q & A

Case 1 – DCIS - Jaspreet Kaur, MD

Case 2 – Inflammatory Breast Cancer - Parminder Sidhu, MD

Case 3 – Early Stage Breast Cancer - Jankikeerthika Dharmarpandi, MD


04:35 PM – 04:40 PM  Adjourn

DoubleTree by Hilton Hotel Fresno Convention Center
2233 Ventura St
Fresno, CA 93721
United States

If you are attending this meeting and need to reserve a hotel room, please reserve your room before the cutoff date, April 8th, at the DoubleTree by Hilton Hotel Fresno Convention Center using the link below to take advantage of the discounted group rate of $189 per night plus applicable taxes and fees:

Click here to make a reservation.

IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:

All conflict of interest has been identified and mitigated for individuals in control of contents.

PLANNING COMMITTEE DISCLOSURE STATEMENT:

None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.

 

Course Director(s)

Binay Shah, MD, MHA

has no relevant financial relationships to disclose at this time.
Conference Chair(s)

Haifaa Abdulhaq, Clinical Professor, UCSF. Director of Hematology, UCSF Fresno. Director of Hematolog/Oncology Fellowship, UCSF Fresno

has a financial relationship (Professional Services) with Abbvie;.
has a financial relationship (Professional Services) with Morphosys;.
has a financial relationship (Professional Services) with Novartis;.
has a financial relationship (Professional Services) with Genentech;.
has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with Kite;.

Sanjay Hinduja

has no relevant financial relationships to disclose at this time.
Speaker/Topic Presenter(s)

Karen Anderson, Professor, Arizona State University, Mayo Clinic Arizona

has a financial relationship (Stock Options) with FlexBioTech;.
has a financial relationship (Independent contractor) with Effector;.
has a financial relationship (Grant Or Contract) with Merck;.

Mohammed BUKARI

has no relevant financial relationships to disclose at this time.

Alfred Chung, Assistant Professor

has a financial relationship (Financial Support) with Carsgen;.
has a financial relationship (Travel) with Janssen;.
has a financial relationship (Financial Support) with Abbvie;.
has a financial relationship (Financial Support) with Merck;.
has a financial relationship (Financial Support) with Bristol Myers Squibb;.
has a financial relationship (Financial Support) with Janssen;.
has a financial relationship (Financial Support) with Cellectis;.
has a financial relationship (Professional Services) with Janssen;.
has a financial relationship (Financial Support) with Caelum Biosciences;.

Vanessa Kennedy, MD

has a financial relationship (Independent contractor) with Astellas ;.

Aaron Logan, MD, PhD

has a financial relationship (Independent contractor) with Actinium;.
has a financial relationship (Independent contractor) with Amgen;.
has a financial relationship (Independent contractor) with Takeda;.
has a financial relationship (Independent contractor) with Sanofi;.
has a financial relationship (Independent contractor) with Pfizer;.

Mark Pegram, MD

has a financial relationship (Other) with Novartis;.
has a financial relationship (Other) with Astra-Zeneca/Daiichi Sankyo;.
has a financial relationship (Other) with Roche/Genentech;.
has a financial relationship (Other) with Gilead;.

Nhat-Long Pham

has no relevant financial relationships to disclose at this time.

Joseph Tuscano, md

has no relevant financial relationships to disclose at this time.

Christos Vaklavas, M.D., Associate Professor

has a financial relationship (Financial Support) with CytomX;.
has a financial relationship (Employment) with Flatiron;.
has a financial relationship (Professional Services) with Daiichi Sankyo;.
has a financial relationship (Financial Support) with Pfizer;.
has a financial relationship (Financial Support) with AstraZeneca;.
has a financial relationship (Professional Services) with SeaGen;.
has a financial relationship (Professional Services) with AstraZeneca;.
has a financial relationship (Professional Services) with Novartis;.
has a financial relationship (Professional Services) with AstraZeneca;.
has a financial relationship (Financial Support) with H3 Biomedicine;.
has a financial relationship (Professional Services) with Guidepoint;.
has a financial relationship (Professional Services) with Gilead;.
has a financial relationship (Financial Support) with SeaGen;.
Case Presenter(s)

Jankikeerthika Dharmarpandi

has no relevant financial relationships to disclose at this time.

Naseem Esteghamat, MD, MS

has a financial relationship (Other) with Seagen;.

Jaspreet Kaur, MD

has no relevant financial relationships to disclose at this time.

Parminder sidhu

has no relevant financial relationships to disclose at this time.

Cathy Zhang

has no relevant financial relationships to disclose at this time.
Moderator(s)

Matthew Frank, MD PhD

has a financial relationship (Travel) with Kite Pharma-Gilead;.
has a financial relationship (Grant Or Contract) with Adaptive Biotechnology;.
has a financial relationship (Grant Or Contract) with Kite Pharma-Gilead;.
has a financial relationship (Grant Or Contract) with Allogene Therapeutics;.
has a financial relationship (Travel) with Cargo Therapeutics;.
has a financial relationship (Grant Or Contract) with Cargo Therapeutics;.

Li Ge, MD

has no relevant financial relationships to disclose at this time.

Xuan Ge, MD, PhD

has no relevant financial relationships to disclose at this time.

Andy Jang, Assistant Professor of Medicine

has no relevant financial relationships to disclose at this time.

Available Credit

  • 6.50 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.50 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 6.50 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 6.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 6.50 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 6.50 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 6.50 Contact Hours.

If you are interested in exhibiting at this meeting, please visit our exhibit page here - https://education.binayfoundation.org/exhibit-information

 

Price

Cost:
$150.00
Please login or register to take this course.

POLICY ON INDUSTRY EMPLOYEE'S PARTICIPATION IN MARKETING/EDUCATION ACTIVITY AT THE CONFERENCE: 

All marketing and product promotion activities must occur in the designated exhibit hall or product theater space separate from the area where this accredited continuing education takes place. 

The exhibit and product promotion space is reserved only for companies that have purchased marketing and product promotion slots at the conference.  The individual registration fee doesn't include marketing or product theater privileges. Please refer to the sponsorship handbook for the types of marketing activities included in your display/sponsorship fees. 

If your company has NOT purchased a marketing opportunity such as an exhibit table, product theater slot or another type of marketing opportunity, you may not participate in any marketing activity or attempt to educate healthcare providers about your product or service. Industry attendees of companies without marketing opportunities must refrain from interacting with healthcare providers at this meeting in any form, including introducing themselves as an employee of the company, discussing the care of patients, handing out flyers and brochures, inviting participants to the company's other programs, etc.

Violating this policy will result in a fine equivalent to a general display fee for that conference. 

If your company has purchased an exhibit or sponsorship, please register at the link below to receive the discounted registration fees:

Link to register as an additional rep of a sponsoring company: https://education.binayfoundation.org/industry_registraiton_nocme .

NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:

If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:

  • If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
  • If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event. 
  • If your company has NOT purchased a display table at the event AND you attended the meeting paying a full industry registration fee, BUT YOU PARTICIPATED IN MARKETING AND PROMOTIONAL ACTIVITIES, you will be billed a full GENERAL DISPLAY FEE for that event. 

Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.

CANCELLATION POLICY

You may cancel your enrollment at any time. Cancellation fees apply as below:

  • 50% of the paid registration fee will be refunded if registration is canceled six weeks before the conference.
  • No refunds will be issued if registration is canceled after that date.  

No credits will be offered if you do not complete all required steps of this activity, including registration and participation in the live meeting.